Correction to “Homologous Tumor Cell-Derived Delivery of Doxorubicin via Liquid Nitrogen-Treated 4T1 Cells for Targeted Breast Cancer Therapy”
Molecular Pharmaceutics · 06.07.2026 · 23 (7) · 3967-3967
DOI: 10.1021/acs.molpharmaceut.6c00585 ↗Kurz gefasst
Korrektur in der Zeitschrift Molecular Pharmaceutics, online erschienen am 01.06.2026. Verfasst von Fangzhou Yang und 9 weiteren Autor:innen. Gefördert von: the Jilin Province Natural Science Foundation of China, CAMS Innovation Fund for Medical Sciences.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
ORCID-Profile: Yifei Guo, Meihua Han
Förderung
- the Jilin Province Natural Science Foundation of China
- CAMS Innovation Fund for Medical Sciences
Zitieren
APA
Yang, F., Lu, Y., Lang, X., Sun, L., Zou, H., Zhou, Z., Guo, Y., Guo, Y., Wang, X., & Han, M. (2026). Correction to “Homologous Tumor Cell-Derived Delivery of Doxorubicin via Liquid Nitrogen-Treated 4T1 Cells for Targeted Breast Cancer Therapy”. Molecular Pharmaceutics, 23(7), 3967-3967. https://doi.org/10.1021/acs.molpharmaceut.6c00585
Vancouver
Yang F, Lu Y, Lang X, Sun L, Zou H, Zhou Z, et al. Correction to “Homologous Tumor Cell-Derived Delivery of Doxorubicin via Liquid Nitrogen-Treated 4T1 Cells for Targeted Breast Cancer Therapy”. Molecular Pharmaceutics. 2026;23(7):3967-3967. doi:10.1021/acs.molpharmaceut.6c00585
BibTeX
@article{Yang2026,
author = {Yang, Fangzhou and Lu, Yunqian and Lang, Xiaoxue and Sun, Lina and Zou, Hang and Zhou, Ziting and Guo, Yaoyao and Guo, Yifei and Wang, Xiangtao and Han, Meihua},
title = {Correction to “Homologous Tumor Cell-Derived Delivery of Doxorubicin via Liquid Nitrogen-Treated 4T1 Cells for Targeted Breast Cancer Therapy”},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {7},
pages = {3967--3967},
doi = {10.1021/acs.molpharmaceut.6c00585}
}
EUVIMED